Published in Neurology on December 09, 2003
Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry (2005) 2.35
Comorbid medical illness in bipolar disorder. Br J Psychiatry (2014) 2.11
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler (2015) 1.80
Sex differences in depressive and socioemotional responses to an inflammatory challenge: implications for sex differences in depression. Neuropsychopharmacology (2015) 1.22
Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. J Neurol Neurosurg Psychiatry (2005) 1.09
High concurrent presence of disability in multiple sclerosis. Associations with perceived health. J Neurol (2007) 1.09
Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Immunol Allergy Clin North Am (2009) 1.08
Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis. Mult Scler (2008) 1.06
Longitudinal course of depression symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry (2006) 1.04
Methodology of an International Study of People with Multiple Sclerosis Recruited through Web 2.0 Platforms: Demographics, Lifestyle, and Disease Characteristics. Neurol Res Int (2013) 1.04
The burden of multiple sclerosis: a community health survey. Health Qual Life Outcomes (2008) 1.03
Variations in functioning and disability in multiple sclerosis. A two-year prospective study. J Neurol (2008) 1.03
Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment. Ther Adv Neurol Disord (2009) 1.02
Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology (2013) 1.02
Predicting employment status in multiple sclerosis patients: the utility of the MS functional composite. J Neurol (2010) 1.01
Comparing CESD-10, PHQ-9, and PROMIS depression instruments in individuals with multiple sclerosis. Rehabil Psychol (2014) 0.99
Neuropsychiatric syndromes associated with multiple sclerosis. J Neurol (2007) 0.96
Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology (2015) 0.95
Depression in multiple sclerosis: a longitudinal analysis. Arch Psychiatr Nurs (2007) 0.94
A population-based study of depressive symptoms in multiple sclerosis in Stockholm county: association with functioning and sense of coherence. J Neurol Neurosurg Psychiatry (2006) 0.94
Unrecognised symptoms of depression in a community-based population with multiple sclerosis. J Neurol (2005) 0.94
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord (2011) 0.94
Psychiatric issues in multiple sclerosis. Psychiatr Clin North Am (2007) 0.94
The association of illness severity, self-reported cognitive impairment, and perceived illness management with depression and anxiety in a multiple sclerosis clinic population. J Behav Med (2007) 0.94
Depressive syndromes in neurological disorders. Eur Arch Psychiatry Clin Neurosci (2013) 0.91
Mind-body medicine for multiple sclerosis: a systematic review. Autoimmune Dis (2012) 0.91
The development of ICF Core Sets for multiple sclerosis: results of the International Consensus Conference. J Neurol (2011) 0.89
Depressogenic effects of medications: a review. Dialogues Clin Neurosci (2011) 0.89
Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis. BMC Psychiatry (2014) 0.89
Self-management for people with multiple sclerosis: report from the first international consensus conference, november 15, 2010. Int J MS Care (2013) 0.88
Sexuality in multiple sclerosis. J Neural Transm (Vienna) (2005) 0.87
Relationships among depressive symptoms, benefit-finding, optimism, and positive affect in multiple sclerosis patients after psychotherapy for depression. Health Psychol (2008) 0.87
Depression, disability and cognitive impairment in multiple sclerosis: a cross sectional Italian study. Neurol Sci (2011) 0.85
Telephone-administered psychotherapy for depression in MS patients: moderating role of social support. J Behav Med (2009) 0.85
Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS). Health Qual Life Outcomes (2010) 0.85
Neuropsychiatric manifestations of multiple sclerosis. Prim Care Companion J Clin Psychiatry (2008) 0.85
Pain affects depression through anxiety, fatigue, and sleep in multiple sclerosis. Rehabil Psychol (2015) 0.84
Determinants of sexual dysfunction in women with multiple sclerosis. BMC Neurol (2013) 0.84
Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis. Biol Psychiatry (2015) 0.84
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Ther Clin Risk Manag (2010) 0.83
Detection of altered hippocampal morphology in multiple sclerosis-associated depression using automated surface mesh modeling. Hum Brain Mapp (2012) 0.82
Impact of psychotherapy on insomnia symptoms in patients with depression and multiple sclerosis. J Behav Med (2010) 0.82
Couples coping with multiple sclerosis: a dyadic perspective on the roles of mindfulness and acceptance. J Behav Med (2012) 0.82
The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord (2011) 0.82
Anxiety, depression and impaired health-related quality of life are therapeutic challenges in patients with multiple sclerosis. Ment Illn (2010) 0.81
Does fatigue complaint reflect memory impairment in multiple sclerosis? Mult Scler Int (2014) 0.80
ApoE alleles, depression and positive affect in multiple sclerosis. Mult Scler (2009) 0.79
Heterogeneity of sickness absence and disability pension trajectories among individuals with MS. Mult Scler J Exp Transl Clin (2015) 0.78
Diagnostic accuracy for major depression in multiple sclerosis using self-report questionnaires. Brain Behav (2015) 0.78
Meditation as an adjunct to the management of multiple sclerosis. Neurol Res Int (2014) 0.78
The relation between Vitamin D status with fatigue and depressive symptoms of multiple sclerosis. J Res Med Sci (2013) 0.78
Impact of depression, fatigue, and global measure of cortical volume on cognitive impairment in multiple sclerosis. Biomed Res Int (2015) 0.77
Use of health services in people with multiple sclerosis with and without depressive symptoms: a two-year prospective study. BMC Health Serv Res (2013) 0.77
Perceived cognitive decline in multiple sclerosis impacts quality of life independently of depression. Rehabil Res Pract (2014) 0.77
Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis. Front Cell Neurosci (2015) 0.77
Co-occurring depression and pain in multiple sclerosis. Phys Med Rehabil Clin N Am (2013) 0.77
Difference in Motor Fatigue between Patients with Stroke and Patients with Multiple Sclerosis: A Pilot Study. Front Neurol (2014) 0.77
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurol (2014) 0.77
How do pain, fatigue, depressive, and cognitive symptoms relate to well-being and social and physical functioning in the daily lives of individuals with multiple sclerosis? Arch Phys Med Rehabil (2017) 0.77
Cross-Sectional Examination of the Associations Between Symptoms, Community Integration, and Mental Health in Multiple Sclerosis. Arch Phys Med Rehabil (2015) 0.76
Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis. Neurol Res Int (2011) 0.76
Variations in and predictors of the occurrence of depressive symptoms and mood symptoms in multiple sclerosis: a longitudinal two-year study. BMC Neurol (2016) 0.76
Selective increase of cerebrospinal fluid IL-6 during experimental systemic inflammation in humans: association with depressive symptoms. Mol Psychiatry (2017) 0.76
Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy: Using Explorys in the MS Population. Int J MS Care (2016) 0.75
Illness comorbidity as a biomarker? J Psychiatry Neurosci (2012) 0.75
Cognitive-constructivist Approach in Medical Settings: The Use of Personal Meaning Questionnaire for Neurological Patients' Personality Investigation. Front Psychol (2017) 0.75
Mood disorder as the presenting manifestation of demyelination. Case Rep Neurol (2013) 0.75
A bidirectional relationship between depression and the autoimmune disorders - New perspectives from the National Child Development Study. PLoS One (2017) 0.75
Deciphering Depressive Mood in Relapsing-Remitting and Progressive Multiple Sclerosis and Its Consequence on Quality of Life. PLoS One (2015) 0.75
Depression as a predictor of occupational transition in a multiple sclerosis cohort. Funct Neurol (2014) 0.75
Poor sleep quality in patients with multiple sclerosis: gender differences. Brain Behav (2016) 0.75
Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis. Brain Behav (2016) 0.75
Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory. PLoS One (2016) 0.75
Psychiatric diagnoses, medication and risk for disability pension in multiple sclerosis patients; a population-based register study. PLoS One (2014) 0.75
Cerebrospinal Venous Outflow in Multiple Sclerosis Patients versus Fatigue and/or Depression. Interv Neurol (2014) 0.75
Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN. Ther Adv Neurol Disord (2016) 0.75
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol (2016) 0.75
Exploration of Undertreatment and Patterns of Treatment of Depression in Multiple Sclerosis. Int J MS Care (2015) 0.75
Magnitude and concurrence of anxiety and depression among attendees with multiple sclerosis at a tertiary care Hospital in Oman. BMC Neurol (2015) 0.75
Progressive multiple sclerosis and mood disorders. Neurol Sci (2015) 0.75
Volunteering for early phase gene transfer research in Parkinson disease. Neurology (2006) 2.27
The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology (2004) 1.66
Group patient visits for Parkinson disease: a randomized feasibility trial. Neurology (2011) 1.57
How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med (2003) 1.54
Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci (2003) 1.53
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry (2005) 1.50
Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology (2011) 1.48
Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev (2005) 1.41
Poverty and mental illness. Can J Psychiatry (1997) 1.29
Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo. Mol Endocrinol (1997) 1.22
The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler (2007) 1.18
Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev (2007) 1.13
Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein. Proc Natl Acad Sci U S A (1991) 1.13
Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. Mol Endocrinol (1992) 1.11
Mortality and cause of death among psychiatric patients: a 20-year case-register study in an area with a community-based system of care. Psychol Med (2009) 1.08
Amitriptyline for depression. Cochrane Database Syst Rev (2007) 1.07
Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler (2000) 1.07
Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry (2005) 1.07
Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol Endocrinol (1995) 1.04
Depression in multiple sclerosis. Psychother Psychosom (1997) 1.04
Major depression and quality of life in individuals with multiple sclerosis. Int J Psychiatry Med (2000) 1.04
Short term predictors of unemployment in multiple sclerosis patients. Can J Neurol Sci (2003) 0.99
The 5'-flanking region of the ovine follicle-stimulating hormone-beta gene contains six progesterone response elements: three proximal elements are sufficient to increase transcription in the presence of progesterone. Endocrinology (1995) 0.99
Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II. J Biol Chem (1994) 0.97
Phosphorylation and progesterone receptor function. J Steroid Biochem Mol Biol (1995) 0.97
Characterization and functional properties of the A and B forms of human progesterone receptors synthesized in a baculovirus system. Mol Endocrinol (1991) 0.96
Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol (2001) 0.96
Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler (2001) 0.94
Avoidable mortality of psychiatric patients in an area with a community-based system of mental health care. Acta Psychiatr Scand (2007) 0.94
Progesterone receptor and the mechanism of action of progesterone antagonists. J Steroid Biochem Mol Biol (1995) 0.93
Determinants of subjective quality of life in patients attending community-based mental health services. The South-Verona Outcome Project 5. Acta Psychiatr Scand (2002) 0.93
Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev (2003) 0.91
Experimental models of neuroprotection relevant to multiple sclerosis. Neurology (2007) 0.91
Pathologic findings in manatees in Florida. J Am Vet Med Assoc (1984) 0.90
Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials. Eur Psychiatry (1996) 0.89
Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Mult Scler (2007) 0.88
What is a multiple treatments meta-analysis? Epidemiol Psychiatr Sci (2012) 0.86
Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. Int J Clin Pract (2013) 0.86
Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes. Mult Scler (2013) 0.85
Low dosage tricyclic antidepressants for depression. Cochrane Database Syst Rev (2003) 0.85
Patterns of disability, care needs, and quality of life of people with Parkinson's disease in a general population sample. Parkinsonism Relat Disord (2012) 0.85
Modulators of cellular protein phosphorylation alter the trans-activation function of human progesterone receptor and the biological activity of progesterone antagonists. Breast Cancer Res Treat (1993) 0.85
Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis. J Psychopharmacol (2008) 0.85
Progesterone stimulation of human insulin-like growth factor-binding protein-5 gene transcription in human osteoblasts is mediated by a CACCC sequence in the proximal promoter. J Biol Chem (1999) 0.85
Cortical white-matter microstructure in schizophrenia. Diffusion imaging study. Br J Psychiatry (2007) 0.84
Exercise prescription after fragility fracture in older adults: a scoping review. Osteoporos Int (2010) 0.84
Mental disorders and conditions specifically related to stress. Epidemiol Psychiatr Sci (2013) 0.83
Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis. Mult Scler (2002) 0.83
Cluster randomised trials. Epidemiol Psychiatr Sci (2011) 0.82
Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder. Acta Psychiatr Scand (2013) 0.82
Implementing a data sharing culture. Epidemiol Psychiatr Sci (2016) 0.81
[The use of psychotropic drugs in an Italian psychiatric hospital: a two-year-long follow-up study]. Epidemiol Psichiatr Soc (2000) 0.81
Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies. Int Clin Psychopharmacol (2002) 0.81
Guideline implementation in mental health: current status and future goals. Epidemiol Psychiatr Sci (2012) 0.81
What is the European Medicines Agency? Epidemiol Psychiatr Sci (2012) 0.81
What is the WHO essential medicines list? Epidemiol Psychiatr Sci (2012) 0.80
Mechanisms controlling steroid receptor binding to specific DNA sequences. Steroids (1991) 0.80
Direct costs of schizophrenia in Italian community psychiatric services. Pharmacoeconomics (2001) 0.80
Dominant perivenular enhancement of tumefactive demyelinating lesions in multiple sclerosis. Neurology (2010) 0.79
Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. BMJ (1992) 0.79
Antidepressant drug prescribing in Italy, 2000: analysis of a general practice database. Eur J Clin Pharmacol (2001) 0.78
3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing-remitting multiple sclerosis: a 3-year pilot study. J Neurol Sci (2010) 0.78
Corpus callosum volume and interhemispheric transfer in multiple sclerosis. Can J Neurol Sci (2010) 0.77
Dichotomizing rating scale scores in psychiatry: a bad idea? Epidemiol Psychiatr Sci (2012) 0.77
Epidemiology of first- and second-generation antipsychotic agents in Lombardy, Italy. Pharmacopsychiatry (2005) 0.76
Fatigue and depression in multiple sclerosis. Can J Psychiatry (2000) 0.76
The two faces of a steroid antagonist: when an antagonist isn't. Steroids (1995) 0.76
High dose oral steroids commonly used to treat relapses in Canadian MS clinics. Can J Neurol Sci (2009) 0.76
Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: An effect size analysis. Eur Psychiatry (1996) 0.75
Olanzapine on trial. Am J Psychiatry (1998) 0.75
Review: atypical antipsychotics are effective adjuncts for treatment resistant depression but increase discontinuation due to adverse effects. Evid Based Ment Health (2008) 0.75
The long march to surrogates of meaningful clinical outcomes in MS trials: are we there yet? Neurology (2011) 0.75
Why it is important to include unpublished data in systematic reviews. Epidemiol Psychiatr Sci (2011) 0.75
Tryptophan and depression. Lancet (1997) 0.75
Regulatory issues in Europe. J Clin Psychopharmacol (2001) 0.75
Clozapine and blood dyscrasias different from agranulocytosis. Can J Psychiatry (1997) 0.75
[Urology in the Republic of Argentina]. Arch Esp Urol (1999) 0.75
Corrections. Pharmacological prevention of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis. Lancet Psychiatry (2015) 0.75
[The lower urinary tract of the chicken]. Rev Argent Urol Nefrol (1970) 0.75
Improving access to medicines for mental disorders in low-resource settings: some achievements but still a long road ahead. Epidemiol Psychiatr Sci (2015) 0.75
Reliability of visual temporal thresholds. Can J Neurol Sci (2007) 0.75
[Ureterovesical reimplantation in ureteral duplication]. Rev Argent Urol Nefrol (1970) 0.75
Identifying reliable change in tactile temporal thresholds in multiple sclerosis: test-retest reliability. Mult Scler (2006) 0.75
[Multiple pathology (nephroureterectomy, partial cystectomy and simultaneous adenomectomy)]. Rev Argent Urol Nefrol (1970) 0.75
Global mental health: achievements, concerns and (unanswered) questions. Epidemiol Psychiatr Sci (2016) 0.75
Social and environmental adversities, neurobiological processes and mental disorders. Epidemiol Psychiatr Sci (2016) 0.75
The National Population Health Survey's assessment of depression risk factor associations: a simulation study assessing vulnerability to bias. Chronic Dis Inj Can (2012) 0.75
Clinical use of the diagnostic criteria for major depressive disorder. Epidemiol Psychiatr Sci (2015) 0.75
What is a factorial trial? Epidemiol Psychiatr Sci (2013) 0.75
Antidepressant agents: from tricyclics to serotonin uptake inhibitors. Psychol Med (1998) 0.75
Evidence-based medicine and medicine-based evidence. Neurol Sci (2005) 0.75
The Qualyop Project. 1: Monitoring the dismantlement of Italian public psychiatric hospitals. Characteristics of patients scheduled for discharge. Int J Soc Psychiatry (1999) 0.75
Italy's mad law. Acta Psychiatr Scand (2000) 0.75
Evidence, knowledge, implementation: glossary of terminology. Epidemiol Psychiatr Sci (2017) 0.75
Tactile temporal thresholds detect relapse-related changes in multiple sclerosis: a preliminary study. Mult Scler (2005) 0.75
Studies of privileged sites and organ transplantation. Exp Nephrol (1994) 0.75
[Rare tumor of the scrotal pouch]. Rev Argent Urol Nefrol (1970) 0.75
Colchicine allows prolonged survival of highly reactive renal allograft in the rat. J Am Soc Nephrol (1993) 0.75